Aclaris Therapeutics, Inc. — Earnings Quality Grade F
ACRS · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR growth 6.7% vs revenue growth -40.1%
Revenue -58.2%, CFFO -134.7%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -99.7% vs revenue -58.2%. Normal
SG&A/Gross Profit = 4053.9%, exceeds 70%
Gross margin swung -10.5pp (17.4% → 6.9%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -11.1%. Low accruals
Insufficient data
Balance Sheet Health
No goodwill. Clean balance sheet
Insufficient data
Other assets -9.6% vs revenue -58.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
Insufficient data
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25